Singapore Clinical Trial: A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating the safety and tolerability of ARD001 in healthy adult subjects and a Phase 2 open-label, multiple-dose study in adult subjects with hemophilia A

Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating the safety and tolerability of ARD001 in healthy adult subjects and a Phase 2 open-label, multiple-dose study in adult subjects with hemophilia A'. The following are the other relevant details related to the trial:

Therapeutic Area: Haematology (General)

Trial Centre(s): SingHealth Investigational Medicine Unit

Trial Status: NA

Principal Investigator(s): Dr Tan Chuen Wen

Published by HT Digital Content Services with permission from Health Daily Digest....